[Malignant head and neck melanoma: Part 2: Therapy].

about

[Malignant head and neck melanoma: Part 2: Therapy].

Item

http://www.wikidata.org/entity/Q54256327

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

[Malignant head and neck melanoma: Part 2: Therapy].

@en

[Malignant head and neck melanoma: Part 2: Therapy].

@nl

type

Item

label

[Malignant head and neck melanoma: Part 2: Therapy].

@en

[Malignant head and neck melanoma: Part 2: Therapy].

@nl

prefLabel

[Malignant head and neck melanoma: Part 2: Therapy].

@en

[Malignant head and neck melanoma: Part 2: Therapy].

@nl

P1476

[Malignant head and neck melanoma: Part 2: Therapy].

@en

P2093

C Pföhler

http://www.w3.org/2001/XMLSchema#string

C S L Müller

http://www.w3.org/2001/XMLSchema#string

T Vogt

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Final version of 2009 AJCC melanoma staging and classification

Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

P2888

s00106-015-0034-5

P304

593-602; quiz 603-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00106-015-0034-5

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26219523

http://www.w3.org/2001/XMLSchema#string